Ajit Kumar Jha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ajit Kumar Jha has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Anup Kumar
Department of Biostatistics and Health Informatics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
2 shared publications- Zia Hashim
Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
2 shared publications Ajmal Khan
Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
1 shared publication- Ajmal Khan
Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
1 shared publication Alok Nath
Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
1 shared publication- Alok Nath
Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow
1 shared publication
Latest Publications
- 16 May 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 258, 108894
Prevalence of relapse in pulmonary sarcoidosis: A systematic review and meta-analysis
- 16 May 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 258, 108894
Prevalence of relapse in pulmonary sarcoidosis: A systematic review and meta-analysis
- Open Access
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Prevalence of Relapse in Pulmonary Sarcoidosis: A Systematic Review
Background and objectiveRelapse after treatment discontinuation or reduction frequently occurs in pulmonary sarcoidosis (PS), but reported rates vary widely. We conducted a systematic review and meta-analysis to estimate relapse prevalence and evaluate risk factors.MethodsWe searched PubMed, Embase, Scopus, and Google Scholar from inception through January 2026 for studies reporting relapse prevalence in PS. Two reviewers independently extracted data on relapse prevalence, timing, definitions, and predictors, and assessed study quality using the Hoy et al. tool. We calculated pooled prevalence using random effects models, assessed heterogeneity using I2, and performed subgroup analyses and meta-regression.ResultsWe included 51 studies comprising 6076 patients; 3682 were followed up, and 1442 relapsed. Pooled relapse prevalence was 0.39 (95% CI, 0.33-0.45) with substantial heterogeneity (I2=94%). Relapse prevalence was lower in prospective (0.31, 95% CI: 0.25-0.37) than retrospective (0.45, 95% CI: 0.36-0.54) studies. Only 23 (45%) studies provided explicit relapse definitions, which varied across clinical, radiological, functional, and biomarker criteria. Advanced radiographic stage was associated with higher relapse odds than stage I (log OR 0.55-1.04, p<0.05), and Black race with higher odds than White race (log OR 0.91, p<0.01). Relapse prevalence did not differ between clinical-only versus composite definitions.ConclusionsApproximately two-fifths of PS patients relapse after treatment reduction or discontinuation. Marked heterogeneity in relapse definitions and observational study designs underscores the need for standardized criteria. Clinical assessment appears comparable to complex definitions for assessing relapse.
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPrevalence of Relapse in Pulmonary Sarcoidosis: A Systematic Review
Background and objectiveRelapse after treatment discontinuation or reduction frequently occurs in pulmonary sarcoidosis (PS), but reported rates vary widely. We conducted a systematic review and meta-analysis to estimate relapse prevalence and evaluate risk factors.MethodsWe searched PubMed, Embase, Scopus, and Google Scholar from inception through January 2026 for studies reporting relapse prevalence in PS. Two reviewers independently extracted data on relapse prevalence, timing, definitions, and predictors, and assessed study quality using the Hoy et al. tool. We calculated pooled prevalence using random effects models, assessed heterogeneity using I2, and performed subgroup analyses and meta-regression.ResultsWe included 51 studies comprising 6076 patients; 3682 were followed up, and 1442 relapsed. Pooled relapse prevalence was 0.39 (95% CI, 0.33-0.45) with substantial heterogeneity (I2=94%). Relapse prevalence was lower in prospective (0.31, 95% CI: 0.25-0.37) than retrospective (0.45, 95% CI: 0.36-0.54) studies. Only 23 (45%) studies provided explicit relapse definitions, which varied across clinical, radiological, functional, and biomarker criteria. Advanced radiographic stage was associated with higher relapse odds than stage I (log OR 0.55-1.04, p<0.05), and Black race with higher odds than White race (log OR 0.91, p<0.01). Relapse prevalence did not differ between clinical-only versus composite definitions.ConclusionsApproximately two-fifths of PS patients relapse after treatment reduction or discontinuation. Marked heterogeneity in relapse definitions and observational study designs underscores the need for standardized criteria. Clinical assessment appears comparable to complex definitions for assessing relapse.